NEW YORK (GenomeWeb) – Building on an earlier test it developed for diagnosing multiple myeloma, Rotterdam, the Netherlands-based SkylineDx has now partnered with a couple of European institutes and a patient advocacy organization to pursue development of a tool that may be able to guide therapy selection for these cancer patients.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.